Company research
NEUROCRINE BIOSCIENCES INC
CIK 914475Updated Sep 27, 2026
SecurityNBIX · NASDAQ · equity
NBIX price & chart
Loading TradingView…
NASDAQ:NBIX on TradingView ↗About the company
Neurocrine Biosciences is a leading biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering, developing and commercializing life-changing treatments for patients with under-addressed neurological, psychiatric, endocrine and immunological disorders. The company’s diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, classic congenital adrenal hyperplasia, hyperphagia in patients with Prader-Willi syndrome, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For more than three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn, X, Facebook and YouTube. (*in collaboration with AbbVie)
In the news
Neurocrine Biosciences Reports Third Quarter 2025 Financial Results News provided by Neurocrine Biosciences, Inc. Oct 28, 2025, 16:01 ET Share this article Share to X Share this article Share to X Achieved Total Net Product Sales of $790 Million Representing 28% Year-Over-Year Growth INGREZZA ® (val ↗
Seeking Alpha
Neurocrine Biosciences, Inc. (NBIX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript ↗
Neurocrine Biosciences, Inc. (NBIX) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript ↗
Neurocrine Biosciences, Inc. (NBIX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript ↗
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 4,631,500,000Source | 3,718,700,000Source | 3,251,400,000Source | 2,368,700,000Source |
| Property, Plant and Equipment, NetUSD | 89,800,000Source | 82,600,000Source | 70,800,000Source | 58,600,000Source |
| GoodwillUSD | — | 5,700,000Source | 5,800,000Source | 5,400,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | — | 36,500,000Source | 35,500,000Source | 37,200,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 713,000,000Source | 233,000,000Source | 251,100,000Source | 262,900,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 686,800,000Source | 479,100,000Source | — | 350,000,000Source |
| Inventory, NetUSD | 69,000,000Source | 57,400,000Source | 38,300,000Source | 35,100,000Source |
| Assets, CurrentUSD | 2,522,700,000Source | 1,724,700,000Source | 1,607,000,000Source | 1,453,500,000Source |
| Operating Lease, Right-of-Use AssetUSD | 455,400,000Source | 509,400,000Source | 276,500,000Source | 87,000,000Source |
| Other Assets, NoncurrentUSD | 59,500,000Source | 15,500,000Source | 49,600,000Source | 25,000,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 1,378,400,000Source | 1,129,000,000Source | 1,019,400,000Source | 660,900,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 100,000Source | 100,000Source | 100,000Source | 100,000Source |
| Retained Earnings (Accumulated Deficit)USD | 447,700,000Source | 29,200,000Source | -157,100,000Source | -406,800,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 13,100,000Source | 5,800,000Source | 7,000,000Source | -7,900,000Source |
| Stockholders' Equity Attributable to ParentUSD | 3,253,100,000Source | 2,589,700,000Source | 2,232,000,000Source | 1,707,800,000Source |
| Additional Paid in Capital, Common StockUSD | 2,792,200,000Source | 2,554,600,000Source | 2,382,000,000Source | 2,122,400,000Source |
| Liabilities and EquityUSD | 4,631,500,000Source | 3,718,700,000Source | 3,251,400,000Source | 2,368,700,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 743,400,000Source | 507,700,000Source | 654,800,000Source | 537,700,000Source |
| Operating Lease, Liability, CurrentUSD | 56,000,000Source | 40,600,000Source | 32,000,000Source | 17,400,000Source |
| Operating Lease, Liability, NoncurrentUSD | 415,300,000Source | 455,100,000Source | 258,300,000Source | 93,500,000Source |
| Other Liabilities, NoncurrentUSD | 219,700,000Source | 166,200,000Source | 106,300,000Source | 29,700,000Source |
| Additional Financial Items | ||||
| Deferred Tax Liabilities, NetUSD | 12,000,000Source | — | — | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 217,900,000Source | 195,500,000Source | 194,300,000Source | 173,100,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 210,500,000Source | 39,800,000Source | 89,300,000Source | 162,200,000Source |
| Increase (Decrease) in InventoriesUSD | 15,300,000Source | 19,100,000Source | -5,400,000Source | 2,600,000Source |
| Deferred Income Tax Expense (Benefit)USD | 164,200,000Source | -123,000,000Source | -60,700,000Source | 22,000,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | 782,700,000Source | 595,400,000Source | 389,900,000Source | 339,400,000Source |
| Cash flows from investing activities: | ||||
| Payments to Acquire Businesses, Net of Cash AcquiredUSD | — | 0Source | 0Source | 42,700,000Source |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -264,400,000Source | -126,800,000Source | -467,100,000Source | -177,100,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 34,000,000Source | 38,200,000Source | 28,300,000Source | 16,500,000Source |
| Cash flows from financing activities: | ||||
| Payments for Repurchase of Common StockUSD | 167,700,000Source | 300,000,000Source | — | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | -38,300,000Source | -486,700,000Source | 65,300,000Source | -234,300,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 480,000,000Source | -18,100,000Source | -11,600,000Source | -73,300,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 721,000,000Source | 241,000,000Source | 259,100,000Source | 270,700,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 0Source | 1,600,000Source | 3,800,000Source | 6,600,000Source |
| Income Taxes Paid, NetUSD | 81,400,000Source | — | — | — |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 0Source | 0Source | 300,000Source | -1,300,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 217,900,000Source | 195,500,000Source | 194,300,000Source | 173,100,000Source |
| Amortization of Debt Issuance CostsUSD | — | — | 700,000Source | 1,200,000Source |
| Amortization of Debt Issuance Costs and DiscountsUSD | — | — | 700,000Source | 1,200,000Source |
| Amortization of Intangible AssetsUSD | 4,100,000Source | 3,600,000Source | 3,500,000Source | 500,000Source |
| DepreciationUSD | 26,000,000Source | 23,500,000Source | 17,800,000Source | 15,100,000Source |
| Equity Securities, FV-NI, Unrealized Gain (Loss)USD | -4,000,000Source | -37,100,000Source | 28,400,000Source | 30,800,000Source |
| Gain (Loss) on Extinguishment of DebtUSD | — | -2,200,000Source | 0Source | -70,000,000Source |
| GoodwillUSD | — | 5,700,000Source | 5,800,000Source | 5,400,000Source |
| Income Tax Expense (Benefit)USD | 226,800,000Source | 144,700,000Source | 82,400,000Source | 59,400,000Source |
| Net Income (Loss) Attributable to ParentUSD | 478,600,000Source | 341,300,000Source | 249,700,000Source | 154,500,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | 478,600,000Source | 341,300,000Source | 249,700,000Source | 154,500,000Source |
| Nonoperating Income (Expense)USD | 86,300,000Source | -84,500,000Source | 81,200,000Source | -35,100,000Source |
| Operating Lease, Impairment LossUSD | 700,000Source | — | — | — |
| Proceeds from Issuance of Common StockUSD | 129,400,000Source | 122,100,000Source | 65,300,000Source | 44,700,000Source |
| Proceeds from Stock Options ExercisedUSD | 115,500,000Source | 110,800,000Source | 55,500,000Source | 37,000,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 2,860,500,000Source | 2,355,300,000Source | 1,887,100,000Source | 1,488,700,000Source |
| Cost of RevenueUSD | 52,100,000Source | 34,000,000Source | 39,700,000Source | 23,200,000Source |
| Gross Profit (Calculated) · Derived | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | 1,156,200,000Source | 1,007,200,000Source | 887,600,000Source | 752,700,000Source |
| Operating Income (Loss)USD | 619,100,000Source | 570,500,000Source | 250,900,000Source | 249,000,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | 705,400,000Source | 486,000,000Source | 332,100,000Source | 213,900,000Source |
| Income Tax Expense (Benefit)USD | 226,800,000Source | 144,700,000Source | 82,400,000Source | 59,400,000Source |
| Net Income (Loss) Attributable to ParentUSD | 478,600,000Source | 341,300,000Source | 249,700,000Source | 154,500,000Source |
| Earnings Per Share, BasicUSD per share | 4.81Source | 3.4Source | 2.56Source | 1.61Source |
| Earnings Per Share, DilutedUSD per share | 4.67Source | 3.29Source | 2.47Source | 1.56Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 99,500,000Source | 100,400,000Source | 97,700,000Source | 95,800,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 102,500,000Source | 103,700,000Source | 101,000,000Source | 98,900,000Source |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 4,100,000Source | 3,600,000Source | 3,500,000Source | 500,000Source |
| Costs and ExpensesUSD | 2,241,400,000Source | 1,784,800,000Source | 1,636,200,000Source | 1,239,700,000Source |
| Current Income Tax Expense (Benefit)USD | 62,600,000Source | 267,700,000Source | 143,100,000Source | 37,400,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | 845,200,000Source | 597,500,000Source | 409,200,000Source | 218,000,000Source |
| Interest ExpenseUSD | — | — | 4,600,000Source | 7,100,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | 478,600,000Source | 341,300,000Source | 249,700,000Source | 154,500,000Source |
| Nonoperating Income (Expense)USD | 86,300,000Source | -84,500,000Source | 81,200,000Source | -35,100,000Source |
Filing attachments
d94926dex991.htm · 8-K · 2026-05-18
EX-99.1 3 d94926dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics Strengthens Neurocrine’s rare disease portfolio with VYKAT™ XR, the first and only approved treatment for hyperphagia in Prader-Willi syndrome Adds recently launched therapy with strong early adoption and meaningful commercial potential SAN DIEGO, May 18, 2026 - Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the completion of its acquisition of S…
Read attachment ↗d110123dex991.htm · 8-K · 2026-04-06
EX-99.1 4 d110123dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio VYKAT TM XR (diazoxide choline) is the First and Only FDA Approved Treatment for Hyperphagia in Prader-Willi Syndrome and Represents a Transformative Therapy Expands Neurocrine’s High-Growth Commercial Portfolio to Three First-in-Class Medicines Including INGREZZA ® (valbenazine) and CRENESSITY ® (crinecerfont) Establishes a Durable…
Read attachment ↗d110123dex992.htm · 8-K · 2026-04-06
EX-99.2 5 d110123dex992.htm EX-99.2 EX-99.2 Neurocrine Biosciences to Acquire Soleno Therapeutics April 6, 2026 Exhibit 99.2 Forward-Looking Statements This communication contains forward-looking statements that involve risks and uncertainties relating to future events and the future performance of each of Soleno and Neurocrine, including statements relating to the ability to complete and the timing of completion of the transactions contemplated by the Agreement and Plan of Merger by and a…
Read attachment ↗